Bioanalytical Systems announced the appointment of John E. Sagartz, DVM, PhD, DACVP, as the Company’s Chief Strategy Officer.
Dr. Sagartz founded and led Seventh Wave Laboratories for over fifteen years prior to BASi’s acquisition of its operations in July of this year. Following the acquisition, Dr. Sagartz joined BASi’s Board of Directors to help guide operations in order to provide broader solutions and greater scientific expertise to the Company’s clients. As Chief Strategy Officer, Dr. Sagartz will help define and accelerate the next phase of growth for the Company.
“John is an outstanding scientist, entrepreneur, and visionary, and I’m excited to have him in this role,” said Dr. Gregory C. Davis, BASi’s Chairman of the Board. “His depth and strength of leadership will be invaluable as our Company grows in the coming months and years. John’s guidance will drive our strategy of delivering operational and service excellence, maximizing our core competencies, and building strategic relationships to facilitate the success of our clients and partners.”
Dr. Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996, and held positions of increasing responsibility as section head, director, preclinical development site head, and fellow, following Monsanto’s merger with Pharmacia. After Pfizer’s acquisition of Pharmacia in 2003, Dr. Sagartz founded Seventh Wave Laboratories where he served as President and Chief Executive Officer, and Chief Strategy Officer.
Dr. Sagartz is an adjunct associate professor of Comparative Medicine at St. Louis University’s College of Medicine and serves on the Board of Directors of the Missouri Biotechnology Association. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.
“Joining with BASi has allowed us to be more strategic in helping clients realize their goals, yet still be of a size to provide personalized service,” said Dr. Sagartz. “As a combined force, we’re seizing the opportunity to strengthen our offerings and create even more value for our clients. We have a great leadership team and I’m excited guide to our strategies as we continue to grow.”